July 2022
Fyarro to require prior authorization for most members, starting Aug. 16
For dates of service on or after Aug. 16, 2022, Fyarro™ (sirolimus protein-bound particles), HCPCS code J9331, will require prior authorization through AIM Specialty Health®. This drug is part of members’ medical benefits, not their pharmacy benefits.
Prior authorization requirements apply when this drug is administered in outpatient settings for:
- Blue Cross Blue Shield of Michigan commercial — Members who have coverage through fully insured groups and members with individual coverage
Note: This requirement doesn’t apply to members who have coverage through Blue Cross commercial self-funded groups, including the Blue Cross and Blue Shield Federal Employee Program® and UAW Retiree Medical Benefits Trust members with Blue Cross non-Medicare plans.
- Medicare Plus Blue℠ members
- Blue Care Network commercial members
- BCN Advantage℠ members
How to submit authorization requests
Submit authorization requests to AIM using one of the following methods:
More about the authorization requirements
Authorization isn’t a guarantee of payment. As always, health care practitioners need to verify eligibility and benefits for members.
For additional information on requirements related to drugs covered under the medical benefit, see:
- Blue Cross commercial and BCN commercial:
- Medicare Advantage:
We’ll update the pertinent drug lists to reflect the information in this message prior to the effective date.
AIM Specialty Health is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services. For more information, go to our ereferrals.bcbsm.com website.
**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website. |